Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742313 · ClinicalTrials.gov registry record · Phase 4
Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT00742313 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 50 participants.
The verdict
NCT00742313, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a prospective, randomized trial to see in patients undergoing coronary artery bypass grafting and endoscopically-harvested greater saphenous vein, if using FloSeal Matrix in the endoscopically-harvested saphenous vein wound bed decreases bleeding and complications.
Interventions
- BIOLOGICAL FloSeal Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742313
The ClinicalTrials.gov registry entry for NCT00742313 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FloSeal Matrix is the first listed.
NCT00742313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00742313 about?
NCT00742313 is a clinical study titled "Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)". This is a prospective, randomized trial to see in patients undergoing coronary artery bypass grafting and endoscopically-harvested greater saphenous vein, if using FloSeal Matrix in the endoscopically-harvested saphenous vein wound bed decreases bleeding and complications.
What is the current status of trial NCT00742313?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2009-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00742313?
The interventions under investigation include: FloSeal Matrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00742313?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.